{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:44:07Z","timestamp":1773492247729,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3349,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)\u2013positive chronic hepatitis B (CHB) were enrolled in a multicenter, double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) 10 mg once daily. There was a significant difference in reduction of serum hepatitis B virus (HBV) DNA after 12 weeks between subjects who received ADV and those who received the placebo (3.4 and 0.1 log10 copies\/mL, respectively,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>&lt; .001). Further reductions in serum HBV DNA and increases in the proportion of subjects with an HBV DNA level of at most 105 copies\/mL, with HBV DNA undetectable, and with ALT normalization were observed in ADV-treated subjects at week 52 (median HBV DNA reduction of 4.5 log10 copies\/mL, 67% with HBV DNA \u2264 105 copies\/mL, 28% with HBV DNA undetectable, and 79% with ALT normalization). Subjects who initially received ADV lost some treatment benefit after being rerandomized to the placebo in week 40. Subjects with YMDD mutant HBV at baseline had virological, biochemical, and serological responses to treatment that were similar to those of subjects with wild-type HBV. The incidence of clinically adverse events was similar in nature and severity between the treatment groups, and there was no evidence of renal toxicity. No adefovir-related HBV mutations were identified.<\/jats:bold>\n                                 <jats:bold>\n                                    In conclusion\n                                 <\/jats:bold>\n                                 <jats:bold>, treatment with ADV 10 mg daily over 52 weeks was safe and effective in Chinese subjects with HBeAg-positive CHB and did not lead to the emergence of drug resistance. The study is continuing for an additional 4 years with all subjects on open-label ADV 10 mg daily.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21225","type":"journal-article","created":{"date-parts":[[2006,6,27]],"date-time":"2006-06-27T07:26:57Z","timestamp":1151393217000},"page":"108-116","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":59,"title":["A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B"],"prefix":"10.1097","volume":"44","author":[{"given":"MinDe","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YiMin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GuangBi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JinLin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YaoZong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beulah N.","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chai-Ni P.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith F.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-17-20241201","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1478-3231.2005.01134.x","article-title":"AsianPacific consensus statement on the management of chronic hepatitis B: a 2005 update.","volume":"25","author":"Liaw","year":"2005","journal-title":"Liver Int"},{"key":"R3-17-20241201","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/hep.20110","article-title":"AASLD chronic hepatitis B: update of recommendations.","volume":"39","author":"Lok","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R4-17-20241201","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as an initial treatment for chronic hepatitis B in the United States.","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Eng J Med"},{"key":"R5-17-20241201","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A oneyear trial of lamivudine for chronic hepatitis B.","volume":"339","author":"Lai","year":"1998","journal-title":"N Eng J Med"},{"key":"R6-17-20241201","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease.","volume":"351","author":"Liaw","year":"2004","journal-title":"N Eng J Med"},{"issue":"S","key":"R7-17-20241201","first-page":"A60","article-title":"Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B.","volume":"16","author":"Guan","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"R8-17-20241201","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","article-title":"Histological outcome during longterm lamivudine therapy.","volume":"124","author":"Dienstag","year":"2003","journal-title":"Gastroenterology"},{"key":"R9-17-20241201","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","article-title":"Prevalence and clinical correlates of YMDD mutants during lamivudine therapy of patients with chronic hepatitis B.","volume":"36","author":"Lai","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R11-17-20241201","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"T, Lim S G, Tong M, Sievert W, Shiffman M, et al. Adefovir dipivoxil for the treatment of Hepatitis B e antigen-positive chronic hepatitis B.","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-17-20241201","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"R13-17-20241201","first-page":"31","article-title":"Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HBeAgpositive chronic hepatitis B (CHB) patients.","volume":"42","author":"Marcellin","year":"2005","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"R14-17-20241201","first-page":"178","article-title":"Adefovir dipivoxil (ADV) demonstrates sustained efficacy in HBeAg chronic hepatitis B (CHB) patients.","volume":"42","author":"Hadziyannis","year":"2005","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"R15-17-20241201","first-page":"660A","article-title":"Longterm safety and efficacy of adefovir dipivoxil (ADV) in the treatment of chronic hepatitis B in patients pre and postliver transplantation (OLT) with lamivudine resistant (LamR) hepatitis B virus (HBV). Abstract.","volume":"40","author":"Schiff","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R16-17-20241201","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/hep.510280629","article-title":"Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.","volume":"28","author":"Xiong","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R17-17-20241201","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/jhep.2000.8626","article-title":"Adefovir dipivoxil for the treatment of lamivudineresistant hepatitis B mutants.","volume":"32","author":"Perrillo","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R18-17-20241201","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(01)05840-8","article-title":"Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV1 and lamivudineresistant hepatitis B virus: an open label pilot study.","volume":"358","author":"Benhamou","year":"2001","journal-title":"Lancet"},{"key":"R19-17-20241201","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/jhep.2003.50288","article-title":"Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.","volume":"38","author":"Westland","year":"2003","journal-title":"HEPATOLOGY"},{"issue":"Suppl 2","key":"R20-17-20241201","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0168-8278(03)80005-3","article-title":"Resistance surveillance of HBeAg chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV).","volume":"38","author":"Xiong","year":"2003","journal-title":"J Hepatol"},{"key":"R21-17-20241201","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0016-5085(03)00939-9","article-title":"Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.","volume":"125","author":"Angus","year":"2003","journal-title":"Gastroenterology"},{"key":"R22-17-20241201","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2003.09.022","article-title":"Selection of a hepatitis B virus strain resistant to adefovir in a liver transplant patient.","volume":"89","author":"Villeneuve","year":"2003","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"R23-17-20241201","first-page":"17","article-title":"Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patents with chronic hepatitis B (CHB).","volume":"42","author":"Locarnini","year":"2005","journal-title":"J Hepatol"},{"key":"R24-17-20241201","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","article-title":"Overview of the SF36 health survey and the International Quality of Life Assessment (IQOL) project.","volume":"51","author":"Ware","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"R25-17-20241201","first-page":"633A","article-title":"Safety profile of 48 weeks of adefovir dipivoxil 10 mg for the treatment of chronic hepatitis B: an integrated analysis of two Phase III studies. Abstract 1882.","volume":"36","author":"Heathcote","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R27-17-20241201","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"Long term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B.","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N Eng J Med"},{"key":"R28-17-20241201","first-page":"889","article-title":"Efficacy of lamivudine in subjects with Hepatitis B e antigennegativehepatitis B virus DNApositive (precore mutant) chronic hepatitis B.","volume":"29","author":"Tassopoulus","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R29-17-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","article-title":"Adefovir dipivoxil alone or in combination with lamivudineresistant chronic hepatitis B.","volume":"126","author":"Peters","year":"2004","journal-title":"Gastroenterology"},{"key":"R30-17-20241201","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(01)05840-8","article-title":"Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV1 and lamivudineresistant hepatitis B virus: an openlabel pilot study.","volume":"358","author":"Benhamou","year":"2001","journal-title":"Lancet"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21225","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200607000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:02:33Z","timestamp":1733058153000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200607000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21225","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}